<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               17    PATIENT COUNSELING INFORMATION <BR>               <BR>                  Advise patients:<BR>                  <BR>                     To report signs and symptoms of infusion reactions such as fever, chills, or breathing problems.<BR>                     Of the potential risks of using Erbitux during pregnancy or nursing and of the need to use adequate contraception in both males and females during and for 6 months following the last dose of Erbitux therapy. <BR>                     That nursing is not recommended during, and for 2 months following the last dose of Erbitux therapy.<BR>                     To limit sun exposure (use sunscreen, wear hats) while receiving and for 2 months following the last dose of Erbitux. <BR>                  <BR>                  —————————————————————————————————<BR>                  Erbitux® is a registered trademark of ImClone LLC a wholly-owned subsidiary of Eli Lilly and Company.<BR>                  Manufactured by ImClone LLC a wholly-owned subsidiary of Eli Lilly and Company, Branchburg, NJ 08876 USA<BR>                  Distributed and marketed by Bristol-Myers Squibb Company, Princeton, NJ 08543 USA<BR>                  Co-marketed by Eli Lilly and Company, Indianapolis, IN 46285 USA<BR>                  <BR><BR>                  <BR><BR>                  Copyright © 2004–2012 ImClone LLC a wholly-owned subsidiary of Eli Lilly and Company, and Bristol-Myers Squibb Company. All rights reserved.<BR>                  <BR><BR>                  1236886B2<BR>                  Rev December 2012<BR>               <BR>               <BR>            <BR>         </P></DIV></HTML>